Gene News and Research

Latest Gene News and Research

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

When people with a family history of colorectal cancer develop the disease, their tumors often carry a molecular sign that the cancer could be life-threatening and may require aggressive treatment, Dana-Farber Cancer Institute scientists report in a new study.

13 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

First Warning Systems announces Letter of Intent with UniCorp Biotech

First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech.

13 Dec 2012

American Association of Anatomist announces winners of Young Investigator Awards

The American Association of Anatomist's (AAA) Young Investigator Awards combine three long-standing AAA awards-Bensley, Herrick, and Mossman-with the Morphological Sciences Award, all recognizing investigators in the early stages of their careers who have made important contributions to biomedical science through their research in cell/molecular biology, developmental biology, comparative neuroanatomy, or the morphological sciences.

12 Dec 2012

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength.

12 Dec 2012

Drugs that bind to specific serotonin receptors can improve and impair female sexual function

Drugs that bind to specific serotonin receptors in the brain can both improve and impair female sexual function in non-human primates.

12 Dec 2012

Scientists determine specific genetic switches that sync liver activity to the circadian cycle

When it's dark, and we start to fall asleep, most of us think we're tired because our bodies need rest. Yet circadian rhythms affect our bodies not just on a global scale, but at the level of individual organs, and even genes.

12 Dec 2012

Link between CTNNA3 gene mutations and arrhythmogenic right ventricular cardiomyopathy

Unfortunately, newspaper articles about young athletes dying suddenly on the field are not unheard of. Such reports fuel discussions about compulsory screening, for example of young footballers, for heart failure. Research by scientists from Ghent (VIB/UGent) and Italy will benefit these screening methods.

12 Dec 2012

Epi-marks can lead to homosexuality

Epigenetics - how gene expression is regulated by temporary switches, called epi-marks - appears to be a critical and overlooked factor contributing to the long-standing puzzle of why homosexuality occurs.

12 Dec 2012

Activated astrocytes could play a harmful role in Alzheimer's disease

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.

12 Dec 2012

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows.

11 Dec 2012

GeneTex to introduce new Histone H3 antibody

GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.

11 Dec 2012

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Gene News and Research

Latest Gene News and Research

Dantrolene may help combat Duchenne muscular dystrophy in boys

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

First Warning Systems announces Letter of Intent with UniCorp Biotech

American Association of Anatomist announces winners of Young Investigator Awards

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Drugs that bind to specific serotonin receptors can improve and impair female sexual function

Scientists determine specific genetic switches that sync liver activity to the circadian cycle

Link between CTNNA3 gene mutations and arrhythmogenic right ventricular cardiomyopathy

Epi-marks can lead to homosexuality

Activated astrocytes could play a harmful role in Alzheimer's disease

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

GeneTex to introduce new Histone H3 antibody

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Weill Cornell research team develops new experimental drug therapy to target DLBCL

uniQure commences acute intermittent porphyria Phase I clinical trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

eBook: Using iPSCs models for human disease research and drug discovery eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices